Memorial Sloan Kettering Cancer Center
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Inclusion Criteria: Patients: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan. Of note, patient does not need to be newly initiating treatment to be eligible for this study. * For patients on NIVO monotherapy or PEMBRO (…
Participants will be randomized to receive nivolumab subcutaneously
Participants will be randomized to receive Nivolumab intravenously
Participants will be randomized to receive Pembrolizumab subcutaneously
Participants will be randomized to receive Pembrolizumab intravenously